Celecoxib Alleviates Zinc Deficiency-Promoted Colon Tumorigenesis Through Suppressing Inflammation

Accumulating evidence has shown that dietary zinc deficiency (ZD) increases the risk of various cancers including esophageal and gastric cancer. However, the role of ZD in colon tumorigenesis is unknown and the related mechanisms need to be investigated. Apc(min/+) mice, widely used to mimic the spontaneous process of human intestinal tumor, were used to construct a ZD mice model in this study. Inflammatory mediators such as COX-2, TNF-alpha, CCL, CXCL, and IL chemokines families were evaluated using real-time PCR and Enzyme-linked immunosorbent assay (ELISA). Besides, the immunoreactivities of cyclin D1, PCNA, and COX-2 in the colon were detected by immunohistochemistry. We found that zinc deficiency could promote colon tumorigenesis in Apc(min/+) mice. The mechanisms are involved in the upregulation of inflammatory mediators: COX-2, TNF-alpha, CCL, CXCL, and IL chemokines families. Administration of celecoxib, a selective COX-2 inhibitor, decreased colon tumorigenesis in Apc(min/+) mice via inhibiting the inflammatory mediators. ZD plays an important role in the process of colon cancers of Apc(min/+) mice. Celecoxib attenuates ZD-induced colon tumorigenesis in Apc(min/+) mice by inhibiting the inflammatory mediators. Our novel finding would provide potential prevention of colorectal tumor-induced by ZD.